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Abstract 56 
Objectives 57 
To evaluate differences in risk factors associated with death due to congestive heart failure (CHF), 58 
arterial thromboembolism (ATE) or sudden death in cats with hypertrophic cardiomyopathy (HCM) 59 
Animals 60 
255 cats with HCM referred to a veterinary teaching hospital. 61 
Methods 62 
Retrospective study.  Cats with HCM were identified that had either died within 2 years of diagnosis or 63 
were known to be alive 2 years after initial examination. Signalment, physical exam, 64 
electrocardiographic and echocardiographic data were analyzed separately for association with death 65 
due to congestive heart failure (CHF) vs. aortic thromboembolism (ATE) vs. sudden death. Results:  66 
Results 67 
Within 2 years of follow-up, 23/255 (9.0%) cats had died with ATE, 44/255 (17.3%) cats had died with 68 
CHF and 12/255 (4.7%) cats had experienced a sudden death, with 141/255 (55.3%) cats still alive at the 69 
end of 2 years. Presence of CHF at presentation and reduced left ventricular fractional shortening (FS%) 70 
were independently associated with a CHF death within 2 years of diagnosis. Presence of ATE and 71 
reduced left atrial fractional shortening (LA-FS%) were independently associated with dying with ATE 72 
within 2 years. No multivariable models were generated for risks of dying a sudden death owing to the 73 
low event rate, but syncope at presentation and arrhythmias on auscultation were associated with 74 
sudden death on univariable analysis. 75 
5 
Conclusions 76 
Asymptomatic cats have a reduced risk of all three types of death. Reduced FS% and a history of CHF 77 
independently predict CHF death, and reduced LAFS% and history of ATE independently predict ATE 78 
death. Sudden death is less commonly reported but is associated with syncope.79 
6 
Hypertrophic cardiomyopathy (HCM) is defined as a hypertrophied, non-dilated left ventricle (LV) in the 80 
absence of other systemic or cardiac disease capable of producing a similar degree of hypertrophy.1  It is 81 
the most common human familial heart disease2, 3 and the most commonly diagnosed feline myocardial 82 
disease.4 HCM is a heterogeneous disease, both in terms of presentation and outcome.  Affected cats 83 
may be asymptomatic, or may show signs associated with congestive heart failure (CHF), arterial 84 
thromboembolism (ATE), syncope or sudden death.  Some cats will die of their cardiac disease but 85 
others may have long survival times and die of non-cardiac causes.5-10  Previous studies have reported 86 
clinical features at presentation in cats that have subsequently died with cardiomyopathy and CHF, ATE 87 
or sudden death. These features include presence of clinical signs, left atrial (LA) enlargement, the 88 
absence of systolic anterior motion of the mitral valve (SAM), increasing age and breed.6-8, 11-13 We have 89 
previously reported reduced LA fractional shortening, left ventricular (LV) fractional shortening and 90 
extreme LV hypertrophy as independent predictors of cardiac mortality in 282 cats with HCM. 91 
Studies evaluating the risk factors for specific types of cardiac death (such as sudden death vs. CHF 92 
death or ATE death) are lacking in cats. An association between LA enlargement and ATE was noted in 93 
one study, and a breed predisposition noted for sudden death in another study, but in general our 94 
understanding is poor of the risk factors predicting death due to CHF instead of ATE or sudden death.  95 
We hypothesized that the risk factors in cats with HCM would be different for death due to CHF 96 
compared with thromboembolic death or sudden cardiac death. The aim of this study was to conduct a 97 
sub-analysis of a previously reported population of cats with HCM to investigate risk factors for different 98 
mortality end-points (CHF death, ATE death and sudden cardiac death).99 
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Animals, Materials and Methods 100 
These data were originally collected to investigate overall survival for this population and as such, the 101 
methods used have been described previously.9 In brief, cases of feline HCM diagnosed by a board-102 
certified cardiologist or a cardiology resident supervised by a board-certified cardiologist at the Royal 103 
Veterinary College, Queen Mother Hospital for Animals (QMHA) on the basis of 2D and/or M-mode 104 
echocardiographya  between June 2004 and August 2009 were included in this study.  Cats were 105 
excluded from the study if they had a concurrent diagnosis of hyperthyroidism or hypertension, defined 106 
as either systolic blood pressure ≥180 mmHg; systolic blood pressure ≥160 mmHg with retinal changes 107 
suggestive of hypertension; medically controlled hypertension; or where renal disease was present and 108 
blood pressure had not been determined.  Cats were also excluded if they were still alive with less than 109 
2 years of follow-up. 110 
The medical records for each cat were reviewed for signalment data, physical exam findings, systolic 111 
arterial blood pressure assessment, serum total thyroxine concentrations, ECG findings, clinical status 112 
and echocardiographic findings.  Clinical status at presentation was recorded and grouped into 113 
asymptomatic, syncope, exertional dyspnea, CHF and ATE.  Congestive heart failure was defined as 114 
present based on previous radiographic evidence of pulmonary edema, ultrasonographic evidence of 115 
pleural or pericardial effusion, or severe tachypnea responsive to furosemide. Cats presented to our 116 
center without congestive signs were designated as having CHF if there was prior evidence of CHF at 117 
either our hospital or the referring practice. Aortic thromboembolism was defined as either sudden 118 
onset painful pulseless limb paresis; central nervous system signs associated with magnetic resonance 119 
imaging findings of a well-demarcated brain lesion, hyperintense on a T2-weighted image; or a history of 120 
                                                          
a Vivid 7, GE Medical Systems Ltd, Hatfield, Hertfordshire, UK 
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acute onset abdominal pain, high creatine kinase levels, and echocardiographic evidence of SEC in the 121 
LA for mesenteric thromboembolism. For the original study, all echocardiographic examinations were 122 
reviewed and remeasured by one board-certified cardiologist (VLF) or a cardiology resident (KB). Details 123 
of echocardiographic measurements are listed in Table 1. Left ventricular hypertrophy was defined as LV 124 
septal or free wall end-diastolic thickness >=6 mm7 in 2D or M-mode measurements.   125 
M-mode images were used to obtain LV fractional shortening (FS%) values whilst 2D images were used 126 
to record maximal LV end-diastolic wall thickness from either the septum or free wall (LVWd).  The 127 
presence of any left ventricular regional wall hypokinesis, subjectively assessed based on 2D images, was 128 
noted.  Presence of systolic anterior motion of the mitral valve (SAM) or mitral regurgitation (MR) was 129 
recorded.   130 
Mortality was determined by reviewing QMHA medical records and contacting referring veterinarians.  131 
Date of death, whether the cat died naturally or due to euthanasia, and whether death was related to 132 
cardiac disease (sudden death, CHF, ATE) or non-cardiac causes was recorded.  Where insufficient 133 
evidence was available, owners were contacted and asked to complete a questionnaire.  Sudden death 134 
was defined as being found dead without obvious cause at home or as a witnessed event where the cat 135 
had been apparently well in the preceding 24 hours, and was assumed to be cardiac.  CHF death was 136 
defined as dying with dyspnea, crackles, cyanosis, fluid pouring out of mouth and/or euthanasia due to 137 
becoming refractory to CHF medication.  ATE death was defined as death or euthanasia following a new 138 
episode of ATE or worsening of a current ATE.  If a cat was alive 2 years after diagnosis it was classified 139 
as alive, irrespective of whether or not further long term follow up was available. 140 
9 
Statistical analysis was performed using commercially available softwareb and values are reported as 141 
mean ± standard deviation (normally distributed data) and median (interquartile range (IQR)) for non-142 
normally distributed data.  Cats reaching a specific end point (sudden cardiac death, CHF death or ATE 143 
death), were compared to a composite of cats that had either died of the other two end points or a non-144 
cardiac death within 2 years of diagnosis or were still alive 2 years after diagnosis (irrespective of their 145 
ultimate outcome).  Univariable analyses on continuous data were performed using t-tests or Mann 146 
Whitney U test as appropriate and for proportions using Chi-squared or Fisher’s exact as appropriate.  147 
Multivariable analysis was performed using binary logistic regression for the outcomes that had at least 148 
20 cats.  Overall model fit was assessed using the Hosmer-Lemeshow test, positive and negative 149 
predictive values from classification tables and assessment of DFBeta and deviance residuals. A value of 150 
p<0.05 was considered statistically significant. 151 
                                                          
b GraphPad Prism 5, GraphPad Software, 2007 and PASW Statistics 20, 2011 
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Results 152 
Between June 2004 and August 2009, 282 cats were diagnosed with HCM.  Of those, 255 had either died 153 
within 2 years of diagnosis or were known to be still alive 2 years after diagnosis.  The other 27 cats 154 
were known to be still alive at the last point of contact but had less than 2 years of follow up and were 155 
therefore excluded.  Most cats were male (75.3%) and neutered (94.5%), and 81.2% were nonpedigree. 156 
Mean body weight was 4.69 +- 1.09 kg. The study population were not different in terms of sex 157 
(p¼1.000), neutering status (p=0.375), breed (p=0.442) or weight (p=0.477) to the 27 excluded cats. The 158 
study population was significantly older (7.0 [3.1-10.0] years) than the excluded 27 cats (3.6 [2.2-7.5] 159 
years, p=0.016). On presentation, the majority (139, 54.5%) of cats were asymptomatic, but 84 (32.9%) 160 
had CHF, 16 (6.3%) had ATE, 13 (5.1%) were presented for syncope and 3 (1.2%) had exertional dyspnea 161 
(Table 2). Of the 16 cats presenting with ATE, four also had CHF but were classed as ATE. Four of the cats 162 
presenting with ATE also had a history of ATE. A minority of cats designated as having CHF (10/84 with 163 
CHF and 2/4 with ATE and CHF) had a history of CHF but were not showing overt signs of congestive 164 
failure at presentation on the visit used in this study. At the initial visit, antithrombotic treatment was 165 
started in 44 (17.3%) cats. Antithrombotic treatment included aspirin (n ¼ 40), clopidogrel (n ¼ 2), or 166 
both aspirin and clopidogrel (n ¼ 2). Of those started on antithrombotic treatment, 15 (34.1%) 167 
subsequently presented with ATE, and 25 (56.8%) presented with CHF. Within 2 years of diagnosis, 168 
79/255 cats had died of their heart disease (31%). Death was associated with CHF in 44 of the 255 169 
(17.3%) cats, ATE in 23 (9.0%) cats, and sudden death in 12 (4.7%) cats. Sixteen (6.3%) cats did not 170 
survive to discharge; eight (50%) cats were euthanized because of noncardiac disease, five (31.3%) were 171 
euthanized because of CHF, two (12.5%) died suddenly and one (6.3%) was euthanized because of ATE. 172 
Of the eight cats euthanized in hospital because of noncardiac disease, seven (87.5%) were classified as 173 
asymptomatic and one cat (12.5%) developed CHF during investigations for neoplastic disease and was 174 
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euthanized because of the neoplastic disease but was classified as having CHF. One of the cats that died 175 
suddenly was witnessed to develop ventricular fibrillation and resuscitation was unsuccessful. Of the 44 176 
deaths due to CHF, 37 (84.1%) were euthanized and seven (15.9%) died spontaneously. Of the 23 deaths 177 
due to ATE, nine (39.1%) also had CHF at the time of death, though they were classed as ATE deaths. 178 
Seventeen (73.9%) of the cats that died because of ATE were euthanized and six (26.1%) died 179 
spontaneously. Other than the two sudden deaths that occurred during the original visit, all sudden 180 
deaths occurred at home. For all the cats that died at home, the primary veterinarian was unaware of 181 
their death and information was gained from the owners. Death was due to noncardiac disease in 35 182 
(13.7%) cats, and 141 (55.3%) cats were still alive 2 years after diagnosis. 183 
CHF death 184 
Cats that died because of CHF were compared to a composite of cats that died suddenly, died because 185 
of ATE, died a noncardiac death or were still alive 2 years after diagnosis. On univariable analysis, the 186 
hazard of a CHF death (Fig. 1) increased with increasing age, presence of an arrhythmia, presenting with 187 
CHF, decreasing left ventricular fractional shortening (FS%), increasing LA size (LA:Ao and LAD), 188 
decreasing left atrial emptying fraction (LA-EF%) and left atrial fractional shortening (LA-FS%), increasing 189 
maximal 2D LVWd, presence of regional wall hypokinesis, presence of SEC/thrombus, and having a 190 
restrictive filling pattern. The hazard of a CHF death was decreased in cats with a murmur, cats that 191 
were asymptomatic at presentation, and cats with SAM. 192 
ATE death 193 
Cats that died because of ATE were compared to a composite of cats that died suddenly, died because 194 
of CHF, died a noncardiac death or were still alive 2 years after diagnosis. The hazard of an ATE death 195 
(Fig. 2) was increased in male cats, cats with a gallop sound, presenting with an ATE, increasing LA size 196 
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(LA:Ao and LAD), decreasing LA-EF% and LA-FS %, increasing maximal 2D LVWd, presence of SEC/ 197 
thrombus and cats with a restrictive filling pattern. The hazard of an ATE death was decreased in cats 198 
that were asymptomatic at presentation. 199 
Sudden death 200 
Cats that died suddenly were compared to a composite of cats that died because of an ATE, died 201 
because of CHF, died a noncardiac death or were still alive 2 years after diagnosis. The hazard of sudden 202 
death (Fig. 3) was increased in cats with an arrhythmia, those with syncope, decreasing FS %, increasing 203 
LA size (LA:Ao and LAD), decreasing LA-EF%, presence of regional wall hypokinesis and presence of 204 
SEC/thrombus. The hazard of sudden death was decreased in cats that were asymptomatic at 205 
presentation. Separate multivariable models were generated for predicting either a CHF death (Table 3) 206 
or an ATE death (Table 4) within 2 years of diagnosis. Presence of CHF at diagnosis and decreasing LV 207 
FS% predicted a CHF death while presence of an ATE at presentation and decreasing LA-FS% predicted 208 
an ATE death. Owing to low numbers of sudden deaths, a multivariable model could not be generated. 209 
Model fit for the CHF model (HosmereLemeshow ¼ 0.329, positive predictive value ¼ 82.4%, negative 210 
predictive value ¼ 90.1%, correctly classified ¼ 89.5%) and for the ATE model (HosmereLemeshow ¼ 211 
0.895, positive predictive value ¼ 88.9%, negative predictive value ¼ 93.7%, correctly classified ¼ 93.5%) 212 
were both considered good. Analysis of the residuals for each model showed good model fit. 213 
 214 
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Discussion 215 
Numerous studies have reported factors associated with a cardiac death in cats with HCM,4, 6-9, 12, 13 216 
including our previous report of the population included in this study,11 but the risk factors have not 217 
been reported separately for CHF vs. ATE or sudden death. If risk factors vary for different forms of 218 
cardiac death, this could have important implications for design of therapeutic trials and the prevention 219 
of these complications of HCM. Although no treatment is known to prevent the onset of CHF in cats with 220 
HCM, antithrombotic treatment is commonly recommended for cats believed to be at risk of ATE, even 221 
though risk factors for ATE have largely been presumed based on clinical experience and anecdotal 222 
evidence.16 Our previous analysis of the cohort of cats with HCM reported here yielded multiple 223 
echocardiographic risk factors for cardiac death, but no attempt was made to link these risk factors with 224 
specific types of mortality end-point.11 We reanalyzed the data from the previous study to evaluate the 225 
specific risk factors for different cardiac mortality end-points: death due to CHF; death due to ATE; and 226 
death due to sudden death. We found that initial clinical presentation remained an important predictor 227 
for all three types of cardiac death, with asymptomatic cats at lower risk of all forms of cardiac 228 
mortality. Multivariable analysis showed CHF on presentation and LV systolic dysfunction to be 229 
independent predictors of CHF death, and ATE on presentation and reduced LA-FS% as independent 230 
predictors of ATE death. Univariable analysis demonstrated an increased risk for sudden death in cats 231 
with a history of syncope, or arrhythmias. In the current population, cardiac mortality was most 232 
commonly associated with CHF (55.7%), then ATE (29.1%) and least commonly sudden death (15.2%). In 233 
the 2002 study by Rush et al.,6 ATE was the most common cause of cardiac death, followed by CHF and 234 
then sudden death. Where type of cardiac death has been reported in survival studies in cats with HCM, 235 
sudden death is usually the least common type of death, but data on prevalence of sudden cardiac 236 
death in cats with HCM are generally scarce. The proportion of sudden deaths reported by owners to 237 
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their own veterinarian is not known. In our cohort, none of the primary veterinarians of the cats that 238 
experienced sudden death at home were aware that the cat had died, supporting the notion of under-239 
reporting. One cat in this study developed ventricular fibrillation, but the cause of sudden death in the 240 
other cats was not known. Alternative possible causes include bradyarrhythmias, coronary or central 241 
nervous systemic thromboembolic events or a thrombus within the LV outflow tract. In people, sudden 242 
cardiac deaths appear to be more common in young adults, with CHF related deaths more common in 243 
middle-aged people, and embolic related deaths more likely to occur in the elderly.10, 44 In the study by 244 
Trehiou-Sechi et al., Maine Coons that died suddenly were younger than other breeds with sudden 245 
death. In our population of cats, CHF deaths within 2 years of diagnosis occurred in older cats than in 246 
those who did not experience a CHF death, but age was not associated with either ATE deaths or sudden 247 
deaths. 248 
Factors previously associated with ATE in the literature include LA enlargement, increased LV diameter, 249 
and SEC. All the LA variables (LA:Ao, LAD, LA-FS%, LA-EF%) were also associated with ATE risk in our 250 
study, as well as SEC or presence of a thrombus, increasing LV wall thickness, presence of a gallop, and 251 
restrictive diastolic filling, but not LV systolic dysfunction or regional wall motion abnormalities. The 252 
multivariable model showed that a history of ATE and reduced LA-FS% were independent predictors. 253 
The initial clinical presentation of the cat was an important predictor of specific mortality endpoints. 254 
Cats presenting with CHF were at increased risk of dying with CHF but not of ATE, and cats presenting 255 
with ATE were at increased risk of dying with ATE but not of CHF. Cats with syncope were more likely to 256 
experience sudden death, although this was only explored at the univariable level because of a low 257 
event rate. Syncope is an important risk factor for sudden death in people and our data suggest this may 258 
also be true in cats. Left atrial variables were predictive of CHF deaths and ATE deaths. Cats with CHF 259 
have been reported to have worse LA function than healthy controls. Left atrial enlargement has 260 
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consistently been one of the most important risk factors reported for cardiac mortality in previous 261 
studies and reduced LA-FS% was an independent predictor of cardiac mortality in the previous overall 262 
survival analysis of the cats in the present study.11 It is therefore likely that a large, poorly contractile 263 
left atrium increases the risk of death due to both CHF and ATE. In human cardiovascular disease, the 264 
presence of SEC has been associated with embolic events and it has been assumed that this is also the 265 
case in cats with HCM.16 In these results, however, SEC appears to predict any type of cardiac end-point 266 
rather than being specific for ATE. Given the previously reported association with SEC and left auricular 267 
appendage velocities, it is likely that SEC is a surrogate marker for LA dysfunction and as such can 268 
predict a CHF or ATE death. At the univariable level LA:Ao, LAD and LA-EF% were predictive of sudden 269 
death. However, it is more difficult to assess the predictive value for sudden death because of low 270 
numbers.  271 
Cats with LV systolic dysfunction (FS% <30%) or regional wall hypokinesis were at increased risk of a CHF 272 
death or sudden death at the univariable level, with FS% <30% being an independent predictor of a CHF 273 
death.  Human HCM patients that have an end-stage phenotype (LV systolic dysfunction, defined as a 274 
left ventricular ejection fraction <50%) are more likely to progress to advanced CHF than those without 275 
systolic dysfunction20, 24, 25 and FS% <30% been reported to be associated with increased risk of 276 
cardiovascular mortality in people.46  The end-stage phenotype of HCM has been suggested as a 277 
predictor of sudden death in people.24, 25 LV systolic function appears to have similar predictive value in 278 
cats as in people, although further work investigating the role in sudden death is required. 279 
In our original survival analysis of this population, LV hypertrophy was an independent predictor of 280 
cardiac mortality and this sub-analysis suggests the increased risk is primarily associated with death due 281 
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to CHF or ATE, which contrasts with findings in people where extreme hypertrophy is associated with an 282 
increased risk of sudden death. 283 
Auscultation findings showed some predictive value at the univariable level, with the presence of a 284 
murmur significantly associated with freedom from a CHF death within 2 years of diagnosis. The 285 
presence of a murmur is often due to the presence of SAM causing dynamic left ventricular outflow tract 286 
obstruction (LVOTO), 8 and SAM was also associated with freedom from a CHF death. A number of feline 287 
studies have reported a similar association between a favorable outcome and a murmur or dynamic 288 
LVOTO. It could be speculated that cats with SAM are detected earlier in their disease course than cats 289 
without SAM because diagnostic investigations are undertaken following detection of a murmur rather 290 
than demonstration of clinical signs, which might explain the apparent survival benefit of both a murmur 291 
and SAM in cats in the short term. There are no studies in cats to evaluate the long term effect of 292 
dynamic LVOTO on cardiac mortality, so it is not clear if cats genuinely differ from people with HCM, in 293 
whom the presence of LVOTO is associated with progression to severe heart failure. 22 Neither the 294 
presence of a murmur nor the presence of SAM was associated with a risk of an ATE death or sudden 295 
death. Gallop sounds were associated with an ATE death but not with a CHF death. Arrhythmias (both 296 
on auscultation and on electrocardiography) were associated with an increased risk of a CHF death or a 297 
sudden death, but it was not possible to analyze individual arrhythmia types because of low numbers. 298 
This is a retrospective study conducted in a referral environment and as such, there are limitations.  299 
Blood pressure was not recorded in every cat, so that it is possible that hypertensive cats were included, 300 
although efforts were made to exclude cats without a blood pressure measurement if they had factors 301 
predisposing to hypertension, such as renal disease.  Serum thyroxine concentrations were not routinely 302 
measured unless clinically indicated and so it is possible that some hyperthyroid cats may have been 303 
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included.  Each cat only had 1 echocardiographic examination measured and used for the study.  As 304 
HCM is a disease that progresses at a variable rate, some cats may have died a cardiac death within two 305 
years of diagnosis without any of the risk factors being obvious at the point of examination.  Therefore 306 
the absence of these risk factors does not exclude the potential for a cat dying within two years of 307 
diagnosis.  At the time of admission some cats were showing signs of CHF and so did not receive a full 308 
echocardiographic examination until stabilized.  Some echocardiographic measurements (eg left atrial 309 
size or function) are likely to have changed during stabilization.  Equally, some cats were already 310 
receiving treatment at admission, which may have affected their echocardiographic measurements.  Not 311 
all echocardiographic measurements were available for every cat, either due to clinician preference, 312 
patient stability or temperament. Owner descriptions and clinical records of referring practices were 313 
used to determine the outcome for the cats.  It is possible that some deaths were missed, particularly as 314 
27 cats could not be included due to lack of follow up data.  Reliance was placed on owner description 315 
for deciding what type of death the cat had experienced.  There were only low numbers of sudden 316 
deaths and ATE deaths within 2 years of diagnosis, limiting the ability to generate meaningful 317 
multivariable models.  Veterinary survival studies are always confounded by variability in selection of 318 
timing for euthanasia versus survival attributable to spontaneous death, and this is also true of our 319 
study. 320 
In conclusion, the most important predictor of the type of cardiac death appears to be symptomatic 321 
status at first presentation, with those presenting with either CHF or an ATE most likely to die of the 322 
same complication within 2 years, and those presenting with syncope are at higher risk of sudden death. 323 
The variables LA:Ao, LAD and LA-EF% were all associated with an increased risk for all three types of 324 
cardiac death. Left atrial fractional shortening was associated with an increased risk for CHF and ATE 325 
deaths. 326 
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Figure 1 – Risk of death due to congestive heart failure (CHF); univariable hazard ratios of physical exam 
and echocardiographic findings at presentation between cats that did and did not suffer a CHF death 
within 2 years of diagnosis.  CHF – congestive heart failure, ATE – arterial thromboembolism, FS% - Left 
ventricular fractional shortening, LA:Ao - short axis ratio of diastolic left atrial diameter to aortic root 
diameter, LAD – the diameter of the left atrium measured parallel with the mitral annulus in the last 
frame before mitral valve opening, LA-EF% – left atrial emptying fraction, LA-FS% – left atrial fractional 
shortening, Max 2D LVWd – maximum end-diastolic left ventricular septal or free wall thickness 
measured on a 2D image, SEC – spontaneous echo contrast, MR – mitral regurgitation, SAM – systolic 
anterior motion of the mitral valve,  a – for a unit change of 1 year, b – for a unit change of 1 beat per 
minute, c – for a unit change of 1 breath per minute, d – for a unit change of 10%, e – for a unit change 
of 1, f – for a unit change of 1 mm 
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Figure 2 - Risk of death due to arterial thromboembolism (ATE); univariable hazard ratios of physical 
exam and echocardiographic findings at presentation between cats that did and did not suffer an ATE 
death within 2 years of diagnosis.  CHF – congestive heart failure, ATE – arterial thromboembolism, FS% 
- Left ventricular fractional shortening, LA:Ao - short axis ratio of diastolic left atrial diameter to aortic 
root diameter, LAD – the diameter of the left atrium measured parallel with the mitral annulus in the 
last frame before mitral valve opening, LA-EF% – left atrial emptying fraction, LA-FS% – left atrial 
fractional shortening, Max 2D LVWd – maximum end-diastolic left ventricular septal or free wall 
thickness measured on a 2D image, SEC – spontaneous echo contrast, MR – mitral regurgitation, SAM – 
systolic anterior motion of the mitral valve,  a – for a unit change of 1 year, b – for a unit change of 1 
beat per minute, c – for a unit change of 1 breath per minute, d – for a unit change of 10%, e – for a unit 
change of 1, f – for a unit change of 1 mm 
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Figure 3 - Risk of death due to sudden death; univariable hazard ratios of physical exam and 
echocardiographic findings at presentation between cats that did and did not suffer a sudden death 
within 2 years of diagnosis.  Nb No pedigree cat died suddenly so it was not possible to generate hazard 
ratios, a chi-squared was non-significant (p=0.130).  No cat that presented with ATE died suddenly so it 
was not possible to generate hazard ratios, a chi-squared was non-significant (p=1.000).  CHF – 
congestive heart failure, ATE – arterial thromboembolism, FS% - Left ventricular fractional shortening, 
LA:Ao - short axis ratio of diastolic left atrial diameter to aortic root diameter, LAD – the diameter of the 
left atrium measured parallel with the mitral annulus in the last frame before mitral valve opening, LA-
EF% – left atrial emptying fraction, LA-FS% – left atrial fractional shortening, Max 2D LVWd – maximum 
end-diastolic left ventricular septal or free wall thickness measured on a 2D image, SEC – spontaneous 
echo contrast, MR – mitral regurgitation, SAM – systolic anterior motion of the mitral valve,  a – for a 
unit change of 1 year, b – for a unit change of 1 beat per minute, c – for a unit change of 1 breath per 
minute, d – for a unit change of 10%, e – for a unit change of 1, f – for a unit change of 1 mm 
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 OR (95% CI) p value 
CHF at first presentation 6.318 (1.699 – 23.496) 0.006 
LA-FS% 0.892 (0.799 – 0.994) 0.039 
FS% 0.965 (0.917 – 0.997) 0.036 
Respiratory rate 1.023 (1.001 – 1.045) 0.045 
Table 1 - Binary logistic regression model, predicting CHF death within two years of diagnosis, (25 events 
of 172 cases) 
 
 OR (95% CI) p value 
ATE at first presentation 28.58 (6.05 – 135.03) <0.001 
LA-FS% 0.84 (0.77 – 0.92) <0.001 
Table 2 – Binary logistic regression model, predicting ATE death within two years of diagnosis, (20 events 
of 200 cases) 
 
